DiaMedica Therapeutics Inc.
DMAC · XNASCIK 1401040fmd_1CAZGS2J4HNN1XRYFADNNPMED6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 1 | – | – | – | – | – | – | – |
| Research and development | 3 | 5 | 8 | 8 | 9 | 8 | 13 | 19 | 25 |
| Total operating expenses | 5 | 7 | 12 | 13 | 14 | 14 | 21 | 27 | 34 |
| Operating income | (5) | (7) | (12) | (13) | (14) | (14) | (21) | (27) | (34) |
| Interest and investment income | – | – | – | – | – | – | 2 | 2 | 2 |
| Other non-operating income (expense) | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 2 | 2 |
| Income before taxes | (4) | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) |
| Net income | (4) | (6) | (11) | (12) | (14) | (14) | (19) | (24) | (33) |